Evogene Ltd.
EVGN
Evogene Ltd. is a computational biology and chemistry company focused on life-science product discovery and development. Evogene uses its proprietary AI-driven platforms to design and optimize small molecules, seed traits, ag-chemicals, ag-biologicals, and other products for agriculture, human health, and industrial applications. Its current business is organized around three segments: Agriculture, Human Health, and Industrial Applications. In agriculture, the company works on crop-improvement solutions such as seed traits and biological or chemical inputs that support plant performance. In human health, it develops microbiome-based therapeutics and related discovery programs. In industrial applications, it pursues specialized biological and seed-based solutions for non-food uses. Headquartered in Rehovot, Israel, Evogene serves as a technology platform company that applies computational methods to accelerate product discovery across multiple sectors.
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$1M
▼ -54.7% YoY
Net Income (TTM)
-$8M
▲ +56.6% YoY
Op. Margin
-1044.30%
▼ -103.3pp YoY
ROIC
-52.94%
▼ -1.3pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$11M
▲ +32.9% YoY
Op. Cash Flow (TTM)
-$11M
▲ +21.2% YoY
Net Debt
-$11M
Net Cash Position
Cash & Equiv.
$13M
3Y CAGR: +32.0%
Continue Research
Peers
Biotechnology · Pick stocks to compare with EVGN
Evogene (EVGN) in four numbers
Questions about Evogene
Is Evogene (EVGN) overvalued?
At $0.30, Evogene's price is 27% above the $0.24 a share fair value that Intrinsiqq's calculator gets from its revenue. The growth behind that figure is yours to set on the Intrinsic Value tab. See how to tell if a stock is overvalued.
What is Evogene's fair value?
Intrinsiqq's calculator puts Evogene's fair value at $0.24 a share. It grows revenue per share 6.4% a year for 5 years, applies an exit P/S of 2.6, and works back at a 10% yearly return. A 25% margin of safety gives a buy-below price of $0.18. Every input can be changed on the Intrinsic Value tab.
Is Evogene a high-quality business?
Evogene scores 25 out of 100 on Intrinsiqq's quality score, which makes it a lower-quality business on these measures. The score blends 6 checks computed from company filings. Its best check is margin trend at +564.1pp, and its weakest is return on capital at -52.9%. The Quality tab shows every check against its target.
Does Evogene (EVGN) pay a dividend?
No. Evogene (EVGN) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: company filings. Price: last close 20 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong?
Download this analysis as a PDF (Pro)
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing EVGN
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.